Patent Oppositions in pain and inflammation drugs industry

Explore the competitive field of pain and inflammation drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in pain and inflammation drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the pain and inflammation drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the pain and inflammation drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 1, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Dosage Forms For Tyk2 InhibitorsBRISTOL MYERS SQUIBBSep 24, 2026SCORPIO
Dosage Forms For Tyk2 InhibitorsBRISTOL MYERS SQUIBBSep 23, 2026SANDOZ
Treatment Of Post-Operative Surgical PainIPSEN BIOPHARMSep 17, 2026MERZ PHARMA
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 10, 2026CAMULON
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 9, 2026LEPTHIEN
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 4, 2026ABEL & IMRAY
Method And Compositions For Inducing Differentiation Of Myeloid Derived Suppressor Cell To Treat Cancer And Infectious DiseasesOSE IMMUNOTHERAPEUTICSSep 3, 2026STRAWMAN
Solid Dosage Forms And Dosing Regimens Comprising (2R,3S,4S,5R)-4-[[3-(3,4-Difluoro-2-Methoxy-Phenyl)-4,5-Dimethyl-5-(Trifluoromethyl) Tetrahydrofuran-2-Carbonyl]Amino]Pyridine-2-CarboxamideVERTEX PHARMACEUTICALS INCORPORATEDSep 3, 2026BARDEHLE PAGENBERG
Solid Dosage Forms And Dosing Regimens Comprising (2R,3S,4S,5R)-4-[[3-(3,4-Difluoro-2-Methoxy-Phenyl)-4,5-Dimethyl-5-(Trifluoromethyl) Tetrahydrofuran-2-Carbonyl]Amino]Pyridine-2-CarboxamideVERTEX PHARMACEUTICALS INCORPORATEDSep 2, 2026DEVA
Crystal Forms Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-CarboxamideBRISTOL MYERS SQUIBBAug 11, 2026HAMPTON KNOWLES

To stay ahead in the competitive pain and inflammation drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the pain and inflammation drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 1, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Aug 20, 2025Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPE12
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
Apr 24, 2024Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA9
Jul 27, 2022Use Of Dpp Iv InhibitorsBOEHRINGER INGELHEIM6
Jul 22, 2020(1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful InflammationsGRNENTHAL5
Feb 25, 2026Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEONE MEDICINES I5
May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE5
Dec 10, 2025Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALS4
Dec 25, 2024Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALS4
Nov 14, 2018Compositions Comprising Bacterial StrainsCJ BIOSCIENCE3